BOLAJI OLUGBOJA: Open Payments
NPI 1689005043 · RANDALLSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$955 in 44 payments from 10 companies in 2025. Trend: 2023 $956 · 2024 $815 · 2025 $955
Food & beverage: $940Education: $15
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $264 |
| Alkermes, Inc. | 12 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| E.R. Squibb & Sons, L.L.C. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Indivior Inc. | 2 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $52 |
| Lundbeck LLC | 2 | $50 |
| ABBVIE INC. | 1 | $25 |
Products named: INGREZZA, ARISTADA, CAPLYTA, FANAPT, COBENFY, REXULTI, SUBLOCADE, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
